Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imipenem cilastatin vs standard-of-care for MDR Pseudomonas aeruginosa infection (prospective cohort)
ChiCTR2600129242Phase 4Not yet recruiting
- Sponsor
- Tongde Hospital of Zhejiang Province
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imipenem + cilastatin in Pseudomonal infection (2 arms), sponsored by Tongde Hospital of Zhejiang Province. Primary endpoints: End-of-Treatment clinical success rate and 28-day all-cause mortality. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
imipenem + cilastatin
03
Conditions
Pseudomonal infection
Beyond the preview
Go deeper on ChiCTR2600129242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129242.